Safe Nanocarriers by Design · Evidence-Ladder Programme 2026–2030
Synthetic-stage rehearsal

An engine that invents brain-cancer nanocarriers — and refuses to harm healthy cells.

Most drug-delivery design chases one number: how hard it hits the tumour. This simulator rehearses a different idea — a generative engine that scores every design it dreams up on a therapeutic window: tumour kill weighed against harm to the healthy brain. Watch it learn to invent safer carriers.

The one idea
Tumour killreward it
Harm to healthy cellspenalise it — harder
Uncertaintydistrust it
safety = kill − λ·harm − γ·uncertainty
A safe carrier must hold this margin across many doses — not just get lucky at one.
01  ·  Why this is hard

In the brain, a toxic miss is permanent

Glioblastoma is among the most lethal cancers. The blood-brain barrier blocks most drugs from reaching it, so carriers like PLGA, Liposomes, Dendrimers, and Gold nanoparticles ferry them across. But the failure that matters most isn't weak tumour kill — it's a carrier that damages healthy neurons, because neuronal loss rarely heals. That is why safety, not raw potency, sits at the centre of every design here.

~5%
five-year survival for glioblastoma, the cancer this targets
4 platforms
PLGA, Liposome, Dendrimer, and AuNP — advanced material structures across the barrier
λ ≥ 1
harm is penalised more than kill is rewarded: 'first, do no harm'
in-vitro
where claims are earned — on real tumour vs. healthy cells, not in simulation
02  ·  Design Workspace

Configure your nanocarrier or run auto-design

Drag the sliders below to manually engineer the nanocarrier, or use the Generative AI panel to let the engine optimize the properties automatically. The Langevin simulation directly underneath displays the physical behavior of your exact formulation in real-time.

Generative AI Auto-Design
Let the genetic algorithm optimize all sliders dynamically. It sweeps the parameter space to maximize the safety index (TWI) under active constraints.
Platform
Payload
Search loops (Epochs)20
More loops yield a more thorough optimization sweep.
Design a carrier by hand
Carrier platform
Therapeutic Payload (Cargo)
Targeting Ligand
Administration Route
Particle size
130 nm
Dendrimers/AuNPs are small (<50nm); PLGA/Liposomes are larger. Smaller crosses the BBB easier, but ultra-small leaks out fast.
Surface charge
-8 mV
Cationic (positive) charge boosts tumor cell uptake, but damages healthy lipid membranes.
Core Rigidity (Stiffness)
45%
Flexible/soft (like liposomes) deforms to squeeze through BBB junctions. Stiff/rigid (like AuNPs) is stable but triggers inflammatory harm.
Shell Hydrophobicity
55%
Higher hydrophobicity boosts membrane fusion and entry but causes aggregation (clumping) and rapid macrophage clearance in blood.
PEG stealth coat
35%
Shields against clearance. Vital for siRNA stability, but over-coating (>70%) blocks cellular entry and ligand binding.
Targeting ligand density
Disabled. Choose a targeting ligand above to enable.
PEG Linker Length
Disabled. Choose a targeting ligand above to enable.
Binding Affinity (Kd)
Disabled. Choose a targeting ligand above to enable.
Release speed
50%
Doxorubicin requires slow/sustained release to bypass P-gp efflux pumps. siRNA works inside cells so speed must match uptake.
Live therapeutic windowTWI 0/100
0255075100low dosehigh doseDOSE →
📌 Benchmark Baseline
📊
No benchmark set
Run the AI optimizer, then lock the best result as your baseline below.
Safe but too weak
Untargeted, TMZ-loaded semi-flexible PLGA Nanoparticle
Kind to healthy cells, but doesn't kill enough tumour to matter.
The PLGA polymeric matrix provides high biocompatibility and facilitates steady, slow release of the therapeutic cargo. The lack of targeting ligands restricts delivery to passive transport, limiting uptake and window width. A PEG stealth density of 35% balances blood half-life extensions with tumor cell entry. The Temozolomide cargo penetrates brain tissue easily, though its moderate potency limits maximum tumor cell kill.
Tumour kill
8%
Healthy harm
6%
Systemic PK Pathway & Loss AnalysisRoute: Intravenous
1
Intake & Gastric AbsorptionNo loss
100% of the nanocarrier formulation enters the bloodstream directly via intravenous injection.
Dose remaining:100.0%
2
Renal Filtration (Kidneys)-2%
Kidney Filtration: Particle size (130 nm) is safely above the renal filtration threshold (~15-20 nm), resulting in negligible renal clearance.
Dose remaining:98.0%
3
Hepatic / RES Clearance-70%
RES Clearance: PEG stealth brush (35%) successfully minimizes macrophage recognition, limiting liver/spleen clearance losses to 70%.
Dose remaining:29.2%
4
Plasma Stability-5%
Plasma Degradation: Small molecule payload (TMZ) is highly stable in plasma, sustaining minimal opsonization/chemical breakdown (5% lost).
Dose remaining:27.7%
5
BBB Transcytosis-81%
BBB Crossing: Passive paracellular diffusion through endothelial junctions, allowing 19% permeability (81% lost).
Dose remaining:5.2%
Live Physical SimulationSimulating: PLGA Carrier (130nm) loaded with TMZ
06 ·  2D Computational Langevin Dynamics

Langevin Microdynamics Sandbox

For a computationally feasible representation of atomic molecular dynamics, we use Langevin/Brownian dynamics. This simulates physical particle advection (blood flow), random thermal diffusion, electrostatic attraction, PEG opsonization, and ligand-receptor binding. Load your highest-scoring TWI champion from the optimizer and watch it behave in real-time.

Real-time Langevin dynamics view
Spawned
0
Cleared
0
Crossed BBB
0
Tumor Kills
0
Tissue Harm
0
Highest TWI Particle
🧬
No TWI champion yet
Run the Generative AI Auto-Design optimizer above to discover the highest-scoring particle. It will appear here automatically.
Current Simulation TWI0/100
Simulating particle geometry
PLGA carrier (130nm) loaded with TMZ
Active targeting: none.
Rigidity: 45%. PEG coating: 35%.
Hydrophobicity: 55%. Linker: N/A.
Affinity: N/A
Langevin Sandbox Rules:
  • Size: Smaller particles diffuse more chaotically (higher random thermal noise).
  • PEGylation: Low PEG leads to rapid immune capture by macrophages (purple blobs).
  • Rigidity: High stiffness rebounds off barrier walls, causing shear-damage (flashes red).
  • Targeting: Targeted ligands bind to receptor points on the cell surface to cross BBB.
03  ·  For the clinically minded

The safety index, defined

Nothing here is hidden behind a black box. The therapeutic-window index is a transparent, dose-resolved quantity — exactly the specification a doctor or methodologist should be able to interrogate.

At a single dose
M(f,d) = K(f,d) − λ·H(f,d) − γ·σ(f,d)
  • K — fraction of tumour cells killed (1 = full kill)
  • H — fraction of healthy cells harmed (0 = none)
  • σ — the model's own uncertainty at that dose
  • λ ≥ 1 — harm-aversion weight (default 2)
  • γ ≥ 0 — uncertainty penalty (default 1)
Across the dose range
TWI(f) = 100 · ∫ max(0, M) dd / ∫ dd

Only positivemargins count — a dose where harm beats kill adds zero, never a bonus elsewhere. So a high score means a genuinely widesafe operating window, not one lucky concentration. A "potent but toxic" carrier — the field's usual winner on raw potency — scores near zero here. That reframe is the whole point.

04  ·  The honest part

This is a rehearsal — not a discovery

A claim should be only as strong as the evidence under it. Everything in this simulator lives on the second rung of a three-rung ladder. It shows the method working; it does not show that any carrier is actually safe.

1Complete
Literature review
A published bibliometric study mapped the field and found the gap. Gives direction, not proof.
2You are here
Synthetic rehearsal
This simulator. Builds and stress-tests the engine on synthetic data. Everything here is a hypothesis.
3The destination
Empirical validation
The real test: engine designs measured on actual tumour and healthy cells in a partner lab. Only here do safety claims become legitimate.

What this can say:"the engine works — it invents novel carriers and optimises a safety objective."  What it cannot say:"this carrier is safe" or "we found the causes of nanocarrier safety." A synthetic result reflects the simulator's assumptions, not biology. It is not a substitute for laboratory or clinical judgment.

Educational simulator built around the BINUS RTTO "Safe Nanocarriers by Design" roadmap (2026–2030). Numbers are illustrative synthetic-stage values. Not medical advice and not a validated design tool.